Helen James

1 week ago | swissinfo.ch | Jessica Davis Plüss |Helen James |Thomas Kern

Hay un mercado en auge de tratamientos, pastillas y artilugios que dicen retrasar el envejecimiento y ayudarnos a vivir más sanos y más tiempo. ¿Funcionan? Illustration: Helen James / SWI swissinfo.ch Escuchar el artículo Escuchando el artículo Toggle language selector Español (europeo) Español (mexicano) Generado con inteligencia artificial.

2 weeks ago | swissinfo.ch | Jessica Davis Plüss |Helen James |Pauline Turuban

The hunt for drugs for diseases that appear or worsen as we get older has become more urgent, and potentially lucrative, for pharmaceutical companies, as the developed world faces an unprecedented demographic shift. Helen James, SWI swissinfo Swiss pharma giant Novartis is re-entering the booming field of ageing research. It wants to develop a blockbuster drug in one of the most rapidly growing, and potentially lucrative, markets: keeping older adults healthy.

1 month ago | swissinfo.ch | Jessica Davis Plüss |Helen James

越來越多的長壽愛好者正在嘗試將雷帕黴素作為抗衰老藥物。 Illustration: Helen James / SWI swissinfo.ch 30多年前，巴塞爾大學分子生物學家麥可‧霍爾(Michael Hall)在研究中發現了一種名為「雷帕黴素靶點」(Target of Rapamycin，簡稱TOR)的基因，這項突破性發現成為多種抗癌藥物研發的基礎。如今，他的開創性成果正推動著醫療健康研究中成長最快、最具營利潛力的領域之一-長壽科學。 此内容发布于 2025年05月08日 - 09:26 16 分钟 Jessica Davis Plüss 我报道瑞士制药行业及医疗健康领域，重点关注药品的获取途径、生物医学创新，以及癌症等疾病的影响。 我在旧金山附近长大，主修国际事务，重点研究发展经济学和医疗政策。在2018年加入瑞士资讯之前，我曾是一名自由记者，并从事商业和人权研究工作。 Helen James (illustration) 相关内容 时事通讯：瑞士媒体里的中国...

1 month ago | swissinfo.ch | Jessica Davis Plüss |Helen James

There is a rapidly growing community of longevity enthusiasts experimenting with rapamycin as an anti-ageing drug. Helen James, SWI swissinfo Listen to the article Listening the article Toggle language selector English (US) English (British) Generated with artificial intelligence.

1 month ago | swissinfo.ch | Jessica Davis Plüss |Helen James

Una comunità in rapida crescita di appassionati di longevità sta sperimentando la rapamicina come farmaco anti-invecchiamento Helen James, SWI swissinfo Oltre 30 anni fa Michael Hall, biologo molecolare dell'Università di Basilea, fece una scoperta rivoluzionaria sul gene Target of Rapamycin, o TOR, che si rivelò fondamentale per lo sviluppo di molti farmaci antitumorali.